Lyon: Maintaining WUXI BIO (02269) outperform market rating, growth acceleration visibility improved.

11:19 23/01/2026

The bank believes that the company has relative resilience, for reasons including a more diversified shareholder structure that helps buffer against geopolitical risks.

Lyon released a research report stating that since January 20th, the stock price performance of WUXI BIO (02269) has outperformed its mainland CRO peers and the overall healthcare sector. The bank believes that the company has relative resilience, due to its more diversified shareholder structure which helps to cushion geopolitical risks; visibility of accelerated growth before 2026 has increased, potential performance may exceed current expectations; as the operating profit of peers in the same industry did not meet expectations in the fourth quarter of 2025, funds flowed back to WUXI BIO. In the mainland CRO/CDMO field, WUXI BIO remains the bank's top pick, with a valuation discount compared to global peers. The target price is 48.5 yuan, with a rating of outperforming the market.

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.

CHINA ITS (01900) subsidiary redeeming private equity fund interests

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.

CHINA ITS (01900) subsidiary redeeming private equity fund interests